LUKE PERIS: Open Payments
NPI 1770613994 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$957 in 29 payments from 7 companies in 2025. Trend: 2023 $801 · 2024 $531 · 2025 $957
Food & beverage: $957
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 10 | $348 |
| Axsome Therapeutics, Inc. | 6 | $241 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $122 |
| Supernus Pharmaceuticals, Inc. | 6 | $121 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $76 |
| Corium, LLC | 1 | $25 |
| Janssen Pharmaceuticals, Inc | 1 | $23 |
Products named: REXULTI, Auvelity, CAPLYTA, Qelbree, TRINTELLIX, Azstarys, SPRAVATO.
Industry payments across TX — which companies pay providers there.
